If you only glanced at Pfizer’s headlines this year, with profit swinging from a US$2,885m gain in Q2 2025 to a loss in Q2 2026 despite higher revenue, you might not expect a happy outcome for patient shareholders. For Pfizer shareholders, the return from the start of the year was 25.4%, including dividends. If you had been weighing that decision on 1 January, with patent cliffs and pricing pressure on record, what exactly were you being paid to believe about this business?
The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.
This theme extends beyond Pfizer. See which of 34 healthcare AI stocks may still merit a closer look.
The Two Pfizer Stories Investors Had To Weigh
The shares cost US$24.9 at the start of the period, and anyone buying Pfizer then had to choose between two very different but reasonable stories about what that price implied.
On the optimistic side, the bull narrative set fair value at US$37.92. That view leaned on aging populations, emerging market demand and an assumption that profit margins could rise to 23.1% by 2028, supported by AI driven productivity and manufacturing savings.
The bear case put fair value at US$23.58. That thesis focused on regulatory pressure, patent expiries on drugs like Eliquis and Ibrance, and an assumption that revenue would fall 4.2% a year even as margins edged up to 21.0%.
What The Evidence Did To The Pfizer Story
The July decision to raise Pfizer’s 2026 revenue guidance after Q2 revenue reached US$15,034m supported the optimistic story about demand and cost savings. The same quarter reported a loss of US$256m, with net margin moving from 19.7% in Q2 2025 to 1.7% below zero. This left the profitability leg of that bullish case unproven. Overall, the evidence cut both ways.
The lesson for readers is clear. When a thesis leans on margin expansion, treat revenue guidance as secondary and keep checking the reported net margin and absolute profit before assuming the story is playing out.
What Pfizer’s Current Price Already Assumes
Pfizer trades at US$30.03 today, after a 25.4% return from the start of the year. The selected Narrative’s Fair Value sits below that level, which means its author sees the market already giving Pfizer credit for meaningful progress.
The crux is execution. For today’s price to hold up, a buyer must judge that new obesity and oncology drugs, plus cost savings, offset pricing pressure and earlier impairments.
"Bearish analysts expect Pfizer's revenue growth and margins to stay under pressure as drug pricing reforms, regulatory interventions, and ongoing patent expirations continue to affect earnings quality. The main factor that has to go right is that Pfizer converts its launched, acquired, and late stage pipeline assets in obesity, oncology, and inflammation into durable non COVID revenue that more than compensates for pricing pressure and loss of exclusivity."
One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all
Which Company Could Surprise You Next?
By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.
- Company 1 - 42% below our estimate - builds large LED installations as venues upgrade scoreboards and signage.
- Company 2 - 30% below our estimate - uses tight offshore vessel supply to secure improved contract terms and deployment.
- Company 3 - 18% below our estimate - expands franchise and company-owned teahouses while overseas locations boost sales mix.
Three companies from the same screener. Open every one of the 28 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com